본문 바로가기

business

Anti-cancer Immunotherapy

Anti-cancer immunotherapy is a novel potential treatment that activates
the immune cells in our body to kill the cancer cells.

Comparison with other Immunotherapies

NK cells are the only immune cells that detect abnormal cells such as cancer cells and remove them immediately without any specific antigens. In accordance to this principle, NK cell based anti-cancer immunotherapy is known to be much safer than other immunotherapies.

Item NK Cell Therapy Dendritic Cell (DC) Therapy CAR-T Cell Therapy
Cell type NK Cells Dendritic Cells T-cells
Target Antigens Non-specific Specific Specific
Presence of Antigens None Natural Artificial
Cancer-killing Cells Direct killing Induces T-cell activation Direct killing
Immune response Direct Indirect Direct
Safety High High Low (Able to cause cytokine syndrome.)

Advantages of the novel potential immunotherapy SuperNK

Safety

  • Pre-clinical study confirms safety for clinical trials
  • Clinical trial Phase 1/2a for Non-small cell lung cancer : Approved by the Korean FDA on Dec 14, 2018.
  • Clinical trial Phase 1 for Malignant Neoplasm: Approved by the US FDA on Mar 1, 2019.
  • Clinical trial Phase 1 for Plaque Psoriasis: Approved by the Mexico FDA on Jun 2019.
  • Obtained the Advanced Regenerative Treatment Technology Permit from the Japanese Ministry of Health, Labor, and Welfare’s Regenerative Medicine Committee.

Excellent Anti-cancer Efficacy

Pre-clinical study confirms that SuperNK delays cancer cell growth and inhibits metastasis.

  • Delay of Cancer cell growth

    Outcomes after transplant of gastric cancer graph
  • Prevention of liver metastases in breast cancer

    24 days after transplanting breast cancer

    Super NK injection (n=10) - Large numbers of metastatic spots were observed in the liver

    Super NK injection (n=12) - Almost no metastatic spots were observed in the liver.

Clinical development pipeline Shortcuts


Move to Top